Skip to content

menu

Health Law Pulse logo
HomeAboutContact
Search
Close
RegulatoryEnforcementFDA & Food SafetyTransparencyInternational
View topics Archives
Subscribe

Health Law Pulse

Leading insight on legal developments in the healthcare and life sciences industries.

Pfizer

Subscribe to Pfizer via RSS

COVID-19 update: Availability of the Pfizer vaccine

Photo of Yvonne Puig (US)Photo of Daphne Calderon (US)Photo of Hannah Putnam (US)
By Yvonne Puig (US), Daphne Calderon (US) & Hannah Putnam (US) on September 20, 2021

On September 17, 2021, the US Food and Drug Administration’s (“FDA”) Vaccines and Related Biological Products Advisory Committee rejected Pfizer’s application for the booster shot of its COVID-19 vaccine for all individuals. The advisory committee was tasked with discussing Pfizer’s…

COVID-19 Update: Pfizer-BioNTech Vaccine Approved for Teens

Photo of Yvonne Puig (US)Photo of Daphne Calderon (US)Photo of Jeff Wurzburg (US)
By Yvonne Puig (US), Daphne Calderon (US) & Jeff Wurzburg (US) on May 11, 2021

On May 10, 2021 the U.S. Food and Drug Administration (“FDA”) announced that the Pfizer-BioNTech Emergency Use Authorization (“EUA”) would be expanded to include children ages 12-15.  Previously, the vaccine had been approved for individuals 16 and older.  The press…

Subscribe to Health Law Pulse

Subscribe to this publication

COVID-19 Update: First Person Receives COVID-19 Vaccine in U.S.

Photo of Yvonne Puig (US)Photo of Daphne Calderon (US)Photo of Jeff Wurzburg (US)
By Yvonne Puig (US), Daphne Calderon (US) & Jeff Wurzburg (US) on December 14, 2020

Almost eleven months after the first confirmed coronavirus patient in the State of Washington (HL Pulse post here), the first dose of Pfizer and BioNTech’s COVID-19 vaccine was administered in the U.S. to a critical care nurse a little…

COVID-19 Update: Progress toward a vaccine candidate

Photo of Yvonne Puig (US)Photo of Daphne Calderon (US)Photo of Jeff Wurzburg (US)
By Yvonne Puig (US), Daphne Calderon (US) & Jeff Wurzburg (US) on November 10, 2020

On November 9, Pfizer and its German counterpart BioNTech announced initial clinical results found their coronavirus vaccine candidate to be more than 90 percent effective. Pfizer will wait to seek Emergency Use Authorization (“EUA”) from the US Food and…

Health Law Pulse

Facebook Twitter RSS LinkedIn YouTube
Published by
Norton Rose Fulbright LLP logo
DisclaimerPrivacy policy

About

Stay up-to-date on healthcare enforcement and regulations with the Health Law Pulse. We give you the news and analysis that matter to your business in a quick, easy-to-read format.

Read more

Topics

Archives

Copyright © 2025, Norton Rose Fulbright LLP. All rights reserved.